Pyxis Oncology Relocates Offices, Hints at Officer Changes

Ticker: PYXS · Form: 8-K · Filed: 2025-07-03T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, executive-changes, office-relocation

Related Tickers: PYXS

TL;DR

Pyxis Oncology moved its HQ to Boston, MA. Big changes might be coming with officers/directors.

AI Summary

Pyxis Oncology, Inc. announced on July 1, 2025, a change in its principal executive offices to 321 Harrison Avenue, Boston, MA 02118. This filing also indicates potential changes related to directors, officers, and compensatory arrangements, though specific details are not provided in this excerpt.

Why It Matters

A change in principal executive offices can signal operational shifts or growth for a company. The mention of officer and director changes suggests potential strategic realignments.

Risk Assessment

Risk Level: medium — The filing indicates potential changes in leadership and executive compensation, which can introduce uncertainty and risk.

Key Players & Entities

FAQ

What is the new address for Pyxis Oncology's principal executive offices?

The new address is 321 Harrison Avenue, Boston, Massachusetts 02118.

What is the exact date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is July 01, 2025.

What is the Commission File Number for Pyxis Oncology, Inc.?

The Commission File Number is 001-40881.

What is the IRS Employer Identification Number (EIN) for Pyxis Oncology, Inc.?

The EIN is 83-1160910.

What specific items are indicated for reporting in this 8-K filing?

The filing indicates reporting for Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; and Compensatory Arrangements of Certain Officers.

From the Filing

0000950170-25-093456.txt : 20250703 0000950170-25-093456.hdr.sgml : 20250703 20250702203037 ACCESSION NUMBER: 0000950170-25-093456 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20250701 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250703 DATE AS OF CHANGE: 20250702 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pyxis Oncology, Inc. CENTRAL INDEX KEY: 0001782223 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 831160910 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40881 FILM NUMBER: 251103476 BUSINESS ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 BUSINESS PHONE: (617) 221-9059 MAIL ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 8-K 1 pyxs-20250701.htm 8-K 8-K 0001782223 false 0001782223 2025-07-01 2025-07-01   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): July 01, 2025     Pyxis Oncology, Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-40881 83-1160910 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           321 Harrison Avenue   Boston , Massachusetts   02118 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (617) 453-3596   (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   PYXS   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒       Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 1, 2025, Pamela Connealy, the Chief Financial Officer and Chief Operating Officer of Pyxis Oncology, Inc. (the “Company”), retired from the Company. Ms. Connealy’s retirement from the Company was not the result of any disagreement with the Company’s independent auditors or any member of management on any matter of accounting principles or practices, financial statement disclosure, or internal controls.   In connection with her retirement and subject to her execution and non-revocation of the Company&#8

View on Read The Filing